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Abstract
Background: microRNAs have been established as powerful regulators of gene expression in normal physiological
as well as in pathological conditions, including cancer progression and metastasis. Recent studies have
demonstrated a key role of miR-31 in the progression and metastasis of breast cancer. Downregulation of miR-31
enhances several steps of the invasion-metastasis cascade in breast cancer, i.e., local invasion, extravasation and
survival in the circulation system, and metastatic colonization of distant sites. miR-31 exerts its metastasis-
suppressor activity by targeting a cohort of pro-metastatic genes, including RhoA and WAVE3. The molecular
mechanisms that lead to the loss of miR-31 and the activation of its pro-metastatic target genes during these
specific steps of the invasion-metastasis cascade are however unknown.
Results: In the present report, we identify promoter hypermethylation as one of the major mechanisms for
silencing miR-31 in breast cancer, and in the triple-negative breast cancer (TNBC) cell lines of basal subtype, in
particular. miR-31 maps to the intronic sequence of a novel long non-coding (lnc)RNA, LOC554202 and the
regulation of its transcriptional activity is under control of LOC554202. Both miR-31 and the host gene LOC554202
are down-regulated in the TNBC cell lines of basal subtype and over-expressed in the luminal counterparts.
Treatment of the TNBC cell lines with either a de-methylating agent alone or in combination with a de-acetylating
agent resulted in a significant increase of both miR-31 and its host gene, suggesting an epigenetic mechanism for
the silencing of these two genes by promoter hypermethylation. Finally, both methylation-specific PCR and
sequencing of bisulfite-converted DNA demonstrated that the LOC554202 promoter-associated CpG island is
heavily methylated in the TNBC cell lines and hypomethylated in the luminal subtypes.
Conclusion: Loss of miR-31 expression in TNBC cell lines is attributed to hypermethylation of its promoter-
associated CpG island. Together, our results provide the initial evidence for a mechanism by which miR-31, an
important determinant of the invasion metastasis cascade, is regulated in breast cancer.
Keywords: miR-31, LOC554202, Triple-negative breast cancer, lncRNA, CpG hypermethylation, Invasion-metastasis
cascade
Background
Metastasis is responsible for ~90% of deaths in patients
with solid tumors [1-4], including those originating in
the breast [5-7]. Metastasis has always been portrayed as
the ultimate step of the progressing breast cancers.
Recent evidence, however, indicates that about a third
of women diagnosed with small asymptomatic breast
tumors (~4 mm) already harbor disseminated BC cells
in their bone marrow [8]. Moreover, these micrometas-
tases can remain dormant for years before reemerging
as incurable secondary tumors and surprisingly insensi-
tive to adjuvant chemotherapies that were originally
effective against the primary tumor [9,10]. Adding to
this problem is the fact that BC is a heterogeneous dis-
ease comprised of at least 5 genetically distinct subtypes,
which together are the second leading cause of cancer
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any medium, provided the original work is properly citeddeaths in women in the United States [11-13]. Within
BC subtypes, those classified as Triple-Negative BCs
(TNBCs) exhibit dismal survival rates due to their highly
aggressive and metastatic behavior, and to their propen-
sity to rapidly recur [14-20]. The TNBC subtype is char-
acterized by lack of expression of hormone receptors
(ER-a and PR) and HER2, harbor BRCA1-defects and/
or deficiencies, and remain p53-positive [14,16-20].
Moreover, the absence of novel therapies capable of spe-
cifically targeting this very aggressive TNBC subtype
reflects in part a lack of sufficient knowledge about
TNBC development and progression [2,4,9,21].
microRNAs (miRs) are small noncoding RNAs, usually
20- to 22-nucleotides long, which regulate gene expres-
sion at the post-transcriptional level. To date, close to
1000 human miRs have been identified, which are
thought to regulate more than 50% of human genes.
miRs are now widely regarded as the most powerful reg-
ulators of gene expression in complex cellular processes
including cancer cell invasion and metastasis [1,22-25].
In fact, several miRs, miR-15a, miR-16-1, and let-7
[23,26-30] function as tumor suppressors, and others,
miR-155, miR-17-5p, and miR-21 [23,31,32], possess
oncogenic properties
Several recent reports have identified a major role of
miR31 in cancer metastasis [33-36] With regard to BC,
we reported that miR-31 expression is lost in aggressive
basal-type breast cancer cell lines compared to the non-
invasive luminal counterparts. This observation was
extended to human breastc a n c e rt u m o r sw h e r ew e
found an inverse correlation between miR-31 expression
levels and advanced stages of BC [24]. Also, in our pre-
viously published work, we reported a highly significant
correlation between the expression levels of WAVE3
and advanced stages of BC [37], supporting the function
of WAVE3 as a metastasis promoter protein [38-40].
Linking these observations, we found that miR-31 regu-
lated WAVE3 expression and activity during the inva-
sion-metastasis cascade [24,25]. However, the upstream
mechanisms of transcriptional regulation of miR-31 are
not well understood and are the focus of the present
study.
A recent study has predicted miR-31 to be transcribed
from within the first intron of a host gene, LOC554202,
on human chromosome 9 [41]. Our in silico analyses
have confirmed these findings and suggest that
LOC554202 is transcribed into a long non-coding RNA,
(Lnc)RNA. We also identified a major CpG island
upstream of the miR-31 locus, which also spans the first
exon of LOC554202, suggesting an epigenetic regulation
by methylation of both miR31 and its host gene. Here,
we report that the expression pattern of miR-31 follows
that of LOC554202 in the TNBC basal versus the lumi-
nal BC cell lines, supporting the hypothesis that miR-31
is under the transcriptional regulation as LOC554202.
Next we show that loss of miR-31 expression in the
aggressive TNBC cell lines is a direct consequence of
hypermethylation of its associated promoter which also
regulates LOC554202, the host gene for miR-31. Using
both methylation-specific PCR (MSP) and bisulfite-mod-
ified DNA sequencing, we directly demonstrate that the
miR-31 promoter is heavily methylated in basal TNBC
compared to luminal BC cell lines. Our results not only
identify a novel mechanism for miR-31 regulation but
also clearly support the important role of promoter
methylation in the suppression of miR-31 during tumor
progression.
Results
miR-31 is transcribed from within the intronic sequence
of a long non-coding (lnc)RNA, LOC554202
miR-31 maps to BAC clone RP11-344A7 (Accession
number AL137022) on human chromosome 9, which
also contains 3’ end of a newly identified LncRNA,
LOC554202 (Figure 1A and Ref [41]). Our in silico ana-
lyses that determined the location of miR-31 within the
first intron of LOC554202 also predicted a very strong
CpG island in its associated promoter, upstream of miR-
31 and spanning the first exon of LOC554202 (Figure
1B). Based on these observations, we hypothesized that
(i) LOC554202 is the host gene for miR-31; (ii)a ss u c h ,
the transcriptional regulation of miR-31 follows that of
its host gene LOC554202; and (iii) because of the pre-
sence of a strong CpG island associated with the promo-
ter of LOC554202, both miR-31 and LOC554202 are
epigenetically regulated by promoter methylation.
Experiments were performed to test these predictions.
T h ec o m p l e t es e q u e n c eo ft h ep r o c e s s e dL O C 5 5 4 2 0 2
transcript is 2246-bp long and is transcribed from 4
exons, based on two independently validated NCBI
nucleotide sequences, accession number AK124393 and
accession number NR_027054 [42,43](Ota et al., 2004
and Strausberg et al., 2002). Furthermore, according to
Ensembl database (ensemble.org), the size of the
LOC554202 gene is more than 106 kb (http://useast.
ensembl.org/Homo_sapiens/Location/View?db=otherfea-
tures;g=554202;r=9:21454267-21559697;t=NR_027054.1),
and spans two contiguous BAC clones on human chro-
mosome 9: RP11-344A7 (Accession number AL137022)
and RP11-354P17 (Accession number AL353732). Exon
1 and part of intron 1 map to BAC clone RP11-344A7,
while the remaining sequence of intron 1, miR-31 and
exon 2 to exon 4 map to BAC clone RP11-354P17. A
schematic representation of the LOC554202 and miR-31
loci is depicted in Figure 2, panel A (Figure 2A). We
used genomic DNA PCR to confirm the mapping of the
4 exons of LOC554202 as well as miR-31 to their
respective BAC Clones (Figure 2A). As predicted, exon
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Figure 1 Genomic organization of LCO554202/miR-31 locus and their associated CpG island. A) Schematic representation of the genomic
organization of the LOC554202 gene. BAC clones RP11-344A7 and RP11-354P17 are shown with horizontal open bars. A strong CpG island
spans exon 1 of LOC554202. miR-31 which maps within intron 1 of LOC554202 is shown with a red horizontal bar. The size of each exon and
intron is also shown. The arrows below Exon 1, Exon 3 and Exon 4 represent the location and orientation of the primers used for RT-PCR of
LOC554202. B) The location of the predicted CpG island (blue line) and LOC554202 exon 1 (green line) are shown with respect to the sequence
of Human BAC clone RP11-344A7 on chromosome 9p21.2-22.3, Accession number AL137022, which contains the 5’ end of the LOC554202, the
host Gene of microRNA miR-31. Each vertical bar represents one CpG dinucleotide. Exon 1 of LOC554201 is shown as a red line. C) Schematic
representation of the predicted CpG island and the location of the MSP primers sets and the bisulfite sequencing primers.
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Page 3 of 121 was amplified only from BAC clone RP11-344A7 but
not from BAC clone RP11-354P17, while miR-31 and
exon 2, 3 and 4 were amplified from RP11-P17 but not
from BAC clone RP11-344A7 (Figure 2A).
We also used genomic PCR analysis to show that all 4
exons of LOC554202 and miR-31 can be amplified from
the genomic DNA of each of breast cancer cell lines we
used in this study (Figure 2B). We, therefore, confirmed
the integrity of the LOC554202 gene in these cell lines,
and ruled out gross genomic alterations as a possible
mechanism for the regulation of expression of both
LOC554202 and miR-31.
miR-31 and its host gene LOC554202 are down-regulated
in TNBCs
As a first step, we tested the relationship between
expression levels of miR-31 and LOC554202 in a series
of BC cell lines. We had previously shown that miR-31
is suppressed in the MDA-MB-231 cell line, an
aggressive triple-negative BC of basal subtype, while it is
expressed abundantly in the non-aggressive luminal sub-
type MCF7 cells [24]. We sought to determine whether
this relationship extended to other BC cell lines of lumi-
nal versus basal subtypes. We found a very significant
contrast in the expression profile of miR-31 between the
luminal and basal BC cells. While the mature miR-31 is
highly expressed in luminal BC subtypes, i.e., MCF7,
SKBr3 and T47D cell lines, its expression is significantly
reduced in the triple-negative basal subtypes such as
MDA-MB-231, BT549 and MDA-MB-453S cell lines
(Figure 3A). Similar trend was found for pri-miR-31, the
precursor transcript for the mature miR-31 (Figure 3B).
These data indicate that the loss of miR-31 associates
with the aggressive TNBC cell lines. The expression
profile of LOC554202 mirrors that of miR-31 in these
same cell lines (Figure 3C); LOC554202 is expressed at
significantly lower levels in the TNBC cell lines com-
pared to the luminal counterparts.
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Figure 2 The genomic structure of the LOC554202 miR-31 is preserved in the BC cell lines used in this study. (A) Schematic
representation of the mapping of the LOC554202 exons, the CpG island and miR-31 with respect to BAC clones RP11-344A7 and RP11-354P17.
The mapping was confirmed by genomic PCR analysis. The size of the PCR product of each amplicon is shown on the left. ERVK6 was used as a
positive control for the total genomic DNA. (B) Genomic PCR analysis of each exon of LOC554202 and miR-31 in the BC cell lines used in this
study. The size of the PCR product of each amplicon is shown on the left. ERVK6 was used a positive control for the total genomic DNA.
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Figure 3 miR-31 and its host gene LOC554202 are downregulated in basal TNBC cell lines and highly expressed in luminal non-
invasive BC cell lines. (A and B) Quantitative real-time RT-PCR of the mature miR-31 (A) and the pri-miR-31 (B) in non-malignant breast
epithelial MCF10A, luminal MCF7, SKBr3 and T47D, and basal triple-negative MDA-MB-435S, MDA-MB-231 and BT549 BC cell lines. miR-16 and
RNUB6 were used for normalization. (C) Semi-quantitative RT-PCR of the LOC554202 transcript in the same cell lines. GAPDH was used an
internal control.
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Page 5 of 12miR-31 and its host gene LOC554202 are epigenetically
regulated in the TNBCs
The presence of a strong CpG island at the LOC554202-
associated promoter suggests that transcription of both
this gene and miR-31 may be regulated by methylation
of the LOC554202-associated promoter. We therefore
treated breast cancer cell lines, where expression of
these two genes is down-regulated, with a de-methylat-
ing agent alone or in combination with a de-acetylating
agent and assessed if expression of both LOC554202
and miR-31 was rescued. Treatment of both MDA-MB-
231 and BT549 cells, which express low levels of either
LOC554202 or miR-31, with the de-methylating agent
5Aza2dC resulted in a significant increase in the levels
of both miR-31 (Figure 4A) and LOC554202 (Figure
4B). When these two cell lines were treated with a com-
bination of both 5Aza2dC and the de-acetylating agent
TSA, the expression levels of both genes increased to
levels even higher than those observed with treatment
with the de-methylating agent alone (Figure 4). These
results clearly demonstrate an epigenetic regulation of
both the LOC554202 and miR-31 by DNA methylation
and probably by chromatin acetylation as well.
CpG island methylation plays an important role in
silencing of both the LOC554202 and miR-31 genes
To confirm the involvement of promoter methylation as
a mechanism for gene silencing of both LOC554202 and
miR-31, we used both methylation specific PCR (MSP)
and sequencing of bisulfite-modified DNA to assess the
methylation status of the CpG island in the LCO554202
promoter. MSP of two different regions of the CpG
island (Figure 1C) showed that, while a strong PCR pro-
duct was amplified from the non-malignant breast
epithelial line MCF10A and the luminal BC subtypes
MCF7, SKBr3 and T47D cell lines, using the unmethyla-
tion-specific primers, a PCR product of significantly
lower intensity was detected in the TNBC MDA-MB-
231, BT549 and MDA-MB453S cell lines (Figure 4A).
The opposite results were obtained when we used
methylation-specific primers, where a significantly
strong PCR product was amplified from the cell lines of
TNBC origin compared to the luminal BC subtypes
(Figure 4A). Thus, the CpG island associated with the
LOC554202 promoter is hypermethylated in the cell
lines with low or no expression of either LOC554202 or
miR-31 and is hypomethylated in the BC cell lines
which express both genes at high levels. We further pro-
vided independent confirmation of the methylation sta-
tus of the LOC554202-assocaited CpG island by
sequencing of bisulfite-modified DNA from MCF7,
MDA-MB-231 and BT549. In the MCF7 cell line where
both the host gene LOC554202 and miR-31 are abun-
dantly expressed, the ratio of methylated to
unmethylated nucleotides for the total number of CpG
dinucleotides surveyed was 9/91 (9% methylated and
91% unmethylated) (Figure 5B). On the other hand, in
MDA-MB-231 and BT549 cell lines which express very
low levels of either LOC554202 or miR-31, the methy-
lated/unmethylated ratio was 70/30 and 54/46, respec-
tively. Thus, the MSP data together with bisulfite
sequencing demonstrate that loss of expression miR-31
and its host gene LOC554202 in the TNBC can be
explained, at least in part, by hypermethylation of their
promoter-associated CpG island, and thereby identifies a
novel mechanism for the upstream regulation of miR-31
in TNBC.
Discussion
Altered expression of microRNAs is frequently observed
in human cancer, including ones originating in the
breast [44-46], but the mechanisms underlying their reg-
ulation are poorly understood. We and others have pre-
viously shown that miR-31, a BC metastasis suppressor
gene, is a major contributor to BC progression and
metastasis by regulating a cohort of a pro-metastatic tar-
get genes, including WAVE3 [24], RhoA, Radexin [36]
and several integrin subunits [47] that regulate key steps
in the invasion-metastasis cascade. miR-31 expression
levels are high in early stage BC tumors, allowing for its
pro-invasive, pro-metastatic target genes to remain
under tight control [24,36]. Expression levels of miR-
31diminish as the tumors progress to more invasive
stages [24] and become undetectable in metastatic BC
tumors [36]. Loss of miR-31 expression is accompanied
by concomitant increase in expression of its pro-invasive
and pro-metastatic target genes, therefore, allowing for
the tumor to become more invasive and ultimately
metastasizes [24,36]. In BC mouse models, re-expression
of miR-31 in the triple-negative MDA-MB-231 BC cells,
which do not express endogenous miR-31, almost com-
pletely inhibits the metastatic potential of these cells
without affecting the growth of the primary tumors
while specifically inhibiting its pro-metastatic target
genes ([36] and Sossey-Alaoui, unpublished data). On
the other hand, knockdown of miR-31 in the non inva-
sive luminal MCF7 BC cells results in lifting the inhibi-
tory effect imposed by miR-31 on its target genes and
imparts aggressive and metastatic phenotype to these
cells comparable to observed in MDA-MB-231 cells
[24,36]. Together, these published studies clearly
demonstrate the important role that miR-31 plays dur-
ing the invasion-metastasis cascade of BC tumors.
The mechanisms for upstream regulation of miR-31
leading to its loss during the invasion-metastasis cascade
has been heretofore unknown. In this study, we report
the contribution of epigenetic modifications as a novel
mechanism by which miR-31 is regulated in breast
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Page 6 of 12cancer. First we showed that miR-31 is transcribed from
the intronic sequence of LOC554202, a newly identified
lncRNA. While both miR-31 and its host gene
LOC554202 are expressed abundantly in the non-inva-
sive BC cell lines of luminal subtype, their expression is
lost in more aggressive TNBC cell lines of basal subtype,
clearly suggesting that the transcription regulation of
miR-31 might be under the control of its host gene
LOC554202. Second, we identified a strong CpG island
in the LOC554202-associated promoter, prompting us
to hypothesize that both miR-31 in its host gene might
be regulated by promoter methylation. Indeed, we were
347 bp 
M
a
r
k
e
r
 
M
C
F
1
0
A
 
M
C
F
7
 
M
D
A
-
M
B
-
2
3
1
 
B
T
5
4
9
 
2
3
1
+
5
A
Z
A
2
d
C
+
T
S
 
A
 
B
T
5
4
9
+
5
A
Z
A
2
d
C
+
T
S
A
 
 
N
o
 
R
N
A
 
LOC554202 
GAPDH 
A 
B 
MCF10A  MCF7  MDA-MB-231  BT549 
0
2
4
6
8
MCAF01A MCF7 231 231-5Aza 231+5Aza+TSA BT549 BT549+5Aza BT549+5Aza+TSA
m
i
R
-
3
1
 
F
o
l
d
 
C
h
a
n
g
e
 
p < 0.05 
p < 0.05 
p < 0.05 
p < 0.05 
p < 0.05 
p < 0.05 
932 bp 
Untreated 
5Aza2dC 
TSA 
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Page 7 of 12able to enhance expression of both miR-31 and
LOC554202 in the TNBC cell lines after treatment with
either the methylase inhibitor 5Aza2Cd alone or in com-
bination with the acetylase inhibitor TSA. To further
confirm the contribution of promoter hypermethylation
to the loss of miR-31 in the TNBC cell lines we per-
formed both methylation specific PCR and sequencing
of bisulfite-modified DNA from both luminal (MCF7)
and basal TNBC (MDA-MB-231 and BT549) cell lines.
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Page 8 of 12by these two assays allowed coverage of at least one
third of total length of the CpG island. We found that
while the LOC554201-associated promoter was signifi-
cantly hypermethylated the in basal TNBCs, it was sig-
nificantly hypomethylated in the luminal counterpart,
further confirming that miR-31 expression is regulated
in the TNBCs at least in part by promoter methylation.
It is well established that hypermethylation of CpG
islands associated with specific genes increases during
the growth and progression of the primary tumor, pro-
viding a mechanism to inactivate tumor suppressor
genes, DNA repair genes, cell cycle regulators and tran-
scription factors. Based on our RT-PCR results, treat-
ment of the TNBC cells with 5Aza2Cd or in
combination with TSA enhanced expression of both
miR-31 and its host gene LOC554202 to levels similar
to those found in luminal BC subtypes. The restoration
of miR-31 expression by these maneuvers was also very
significant but did not reach the levels observed in lumi-
nal BC (Figure 3). One possible explanation for this dif-
ference is that, in addition to promoter methylation that
regulates both miR-31 and LOC554202, other mechan-
isms may selectively regulate miR-31.
It is worth noting that our study appears to be the
first to report that LOC554202 might belong to the
lncRNA family. Our preliminary in silico analyses show
that the LOC554202 locus spans more that 100 kilo-
b a s e s( k b )o fg e n o m i cs e q u e n c ea n dt h a ti t sR N Ai s
transcribed from 4 exons resulting in a spliced transcript
of ~2.2 kb (Figure 1), which does not contain an open-
reading frame that could be translated into a functional
protein, and therefore can be classified a lncRNA. It is
possible that this new lncRNA may have a function in
chromatin remodeling and epigenetic regulation of gene
expression similar to that of the well known XIST and
HOTAIR lncRNAs [48,49]. More experimental analyses
are however required to investigate the exact function of
LOC554202 in breast cancer invasion and metastasis.
Conclusion
The present study, although conducted in established cell
lines, clearly identifies promoter hypermethylation as a
novel mechanism by which miR-31 is silenced during the
invasion-metastasis cascade of BC. Future studies using
biological specimens with associated clinico-pathological
parameters and disease outcome, are required to further
confirm these findings and to assess whether miR-31 pro-
moter methylation can be used a prognostic marker for
BC progression and survival outcome.
Methods
Cell lines and their treatment
Human non-malignant breast epithelial cell line
MCF10A and the human breast cancer cell lines were
obtained from American Type Culture Collection (Rock-
ville, MD). Cells were cultured at 37°C with 5% CO2 in
their specified basic culture medium supplemented with
4.5 g/L glucose, 10% fetal bovine serum (Invitrogen), 2
mmol/L glutamine and antibiotics. The demethylating
agent 5Aza2dC (Sigma, MO, USA) was freshly prepared
in double-distilled H2O and filter sterilized. Cells (5-10
×1 0
5) were seeded in a 100 mm tissue culture dish in
culture medium at 37°C, 10% CO2. The next day, cells
were treated with 0.5 μM of 5aza2dC. The culture med-
ium containing the demethylating agent was replaced
every day for 7 days. For the 5Aza2dC-Trichostatin A
(TSA, Sigma, MO, USA) dual treatment, TSA (0.3 μM
final concentration) was added to the culture at day 5
for a 48-h treatment period. At the end of the treatment
period, total RNA was prepared using TRIzol (Invitro-
gen, CA, USA), according to the manufacturer’s instruc-
tions. The BAC clones were obtained from the Rowell
Park Cancer Institute BAC Library and BAC DNA was
isolated using the the QIAprep Spin Miniprep kit (Qia-
gen Sciences, MD, USA). The total genomic DNA was
prepared using proteinase K digestion as previously
described [50].
Semi-quantitative and Real-time quantitative-PCR
Total RNA was extracted from cancer cell lines using
TRIzol reagent (Invitrogen, Carlsbad, CA), following to
the manufacturer’s instructions. cDNA was generated
and used as a template for semi-quantitative RT-PCR
performed as previously described [25,37,51,52]. Expres-
sion levels of the precursor (pri-miR) and the mature
forms of microRNA miR-31 were quantified by real-
time quantitative RT-PCR using human TaqMan Micro-
RNA Assays Kits (Applied Biosystems, Carlsbad, CA).
We used GAPDH to normalize the expression levels of
LOC554202 transcripts. In addition, we found that both
miR-16 and RNU6B were expressed at similar levels in
all cell lines analyzed, when normalized to GAPDH
(Additional File 1). Furthermore, treatment of BC cells
with either 5Aza2dC, Trichostatin A or both, did not
affect their expression levels when compared to the
untreated cells (Additional File 1), and therefore, were
used for normalization of miR-31 expression levels
across the breast cancer cell lines and between treat-
ments. The reverse transcription reaction was carried
out with TaqMan MicroRNA Reverse Transcription Kit
(Applied Biosystems, Carlsbad, CA) following the manu-
facturer’s instructions. Quantitative PCR was performed
on the BioRad (Hercules, CA) MyiQ2 iCycler PCR sys-
tem where the reaction mixtures were incubated at 95°C
for 10 min, followed by 40 cycles of 95°C for 15 s and
60°C for 1 min. The cycle threshold (Ct) values were
calculated with SDS 1.4 software (Bio-Rad). The expres-
sion levels of miR-31 were normalized using the 2
-ΔΔCt
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calculated by subtracting the Ct values of miR-16 from
the Ct values of miR-31. The ΔΔCt was then calculated
by subtracting ΔCt of each breast cancer cell line from
MCF10 cells. Fold change in the gene expression was
calculated according to the equation 2
-ΔΔCt.
Preparation of bisulfite-modified DNA for methylation
analysis
Genomic DNA (1-2 μg) was denatured in 0.3 M NaOH
for 30 min at 42°C, and then the unmethylated cytosine
residues were sulphonated by incubation in 3.12 M
sodium bisulfite (pH 5.0; Sigma)/5 mM hydroquinone
(Sigma, MO, USA) at 55°C for 16 h. The sulphonated
DNA was recovered using the QIAquick Gel Extraction
system (Qiagen, MA, USA), according to the manufac-
turer’s recommendations. The conversion reaction was
completed by desulphonating in 0.3 M NaOH for 5 min
at room temperature. The DNA was ethanol precipi-
tated and resuspended in double-distilled water.
CpG island prediction and primer design for methylation
analysis
The LOC554202 putative promoter region was predicted
from the genomic sequence of BAC clone RP11-344A7,
accession number AL137022, for the sequence around
its first exon using the PromoterInspector prediction
software (http://www.genomatix.ed). The promoter-asso-
ciated CpG island was predicted using the CpG predic-
tion algorithm (http://www.urogene.org/methprimer/
help.html#cpg_prediction), and primers for sequencing
of bisulfite-modified DNA and for methylation specific
PCR (Additional File 2) were designed using the Meth-
primer algorithm (http://www.urogene.org/methprimer/
index.html).
Sequencing of bisulfite-modified DNA
In total, 20-50 ng of bisulfite-treated DNA was used as
template in each PCR reaction under the following con-
ditions: 95°C for 5 min, followed by 40 cycles of 15 s of
denaturation at 95°C, 20 sec at 55°C and 25 sec of
extension at 72°C. The PCR reaction was terminated
with an additional 7 min of extension and cooled to 4°
C .T h eP C Rp r o d u c t sw e r er e s o l v e do na2 %a g a r o s e
gel, stained with ethidium bromide, and the 250-bp
bands were excised and gel-purified using the QIAquick
Gel Extraction system (Qiagen, MA, USA). The purified
PCR products were cloned into the pCR2·1-TOPO vec-
tor (Invitrogen, CA, USA), and at least 15 clones were
sequenced from each cell line. The methylation status at
each CpG site was analyzed using the MethTools soft-
ware (http://genome.imb-jena.de/methtools/). The over-
all methylation status in each cell line was calculated as
a ratio of the number of unmethylated to methylated
CpGs and plotted as a percentage of total number of
CpGs analyzed.
Methylation specific PCR
Methylation specific PCR (MSP) was performed on bisu-
fite-converted DNA using the MSP primer pairs
described in Additional file 2. Each DNA sample was
PCR-amplified using either the methylated or the
unmethylated primer pairs. The PCR products were
next resolved by agarose electrophoresis, stained with
ethidium bromide and a picture recorded. The intensi-
ties of the PCR products between the methylated and
unmethylated primer-pairs were compared by
densitometry.
Oligonucleotide primer sequences
Sequences of the oligonucleotide primers used for geno-
mic PCR, RT-PCR from IDT (San Diego, CA) and are
listed Additional file 2.
Statistical analyses
The data are presented as the means ± standard errors
of at least three independent experiments. The results
were tested for significance using an unpaired Student’s
t test and p values of < 0.05 were considered statistically
significant.
Additional material
Additional file 1: Quantitative real-time RT-PCR of miR-16 (A and B)
and RNU6B (C and D) in the indicated cell lines as well as before
and after treatment with 5Aza-2dC and TSA. GAPDH was used as an
internal control for normalization.
Additional file 2: List of oligonucleotide primers and microRNA
assays used in this study.
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